Datopotamab Deruxtecan
Triple-Negative Breast Carcinoma
Explore 428 assets in Triple-Negative Breast Carcinoma →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07069595CT.gov PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease | — | Recruiting | — | — | — |
NCT06954480CT.gov Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT06176261CT.gov DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | — | Recruiting | — | — | — |
NCT05460273CT.gov A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | — | Active Not Recruiting | — | — | — |
NCT03742102CT.gov A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03401385CT.gov First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | — | Active Not Recruiting | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Datopotamab Deruxtecan (this asset) | UNC Lineberger Comprehensive Cancer Center | P2 | B · 56 |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Veliparib | National Cancer Institute (NCI) | P3 | BB |
| Enzalutamide | Nuvation Bio Inc. | P2 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Datopotamab Deruxtecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 63 |
| Stomatitis | — | P4 | B · 61 |
| Biliary Tract Cancer | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Datopotamab Deruxtecan in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/datopotamab-deruxtecan-triple-negative-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →